EUVIMEDОткрийте EUVIMED
Open access · CC BY 4.0

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang iD, Houshi Xu iD, Peng Wang, Yue Wang and 11 more

Advanced Science · 2026

DOI: 10.1002/advs.76216 ↗

At a glance

Journal article in Advanced Science, 2026. Written by Jiawen Chen and 22 co-authors. Institution: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Glioblastoma, Boron Neutron Capture Therapy, Nanoparticles, Immunotherapy. Cited 1 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Excellent project of Shanghai Municipal Health Commission.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10 B(n, α)‐ 7 Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional boron agents and their failure to achieve therapeutic intracranial concentrations. Here, we design macrophage membrane‐coated PLGA nanoparticles (M@PLGA‐ 10 BN) that exploit innate biological transport mechanisms to overcome dual therapeutic barriers. The macrophage membrane enables: (i) α 4 β 1 integrin‐mediated BBB transmigration via VCAM‐1 binding, (ii) chemokine‐directed tumor tropism, and (iii) CD47‐dependent immune evasion. In orthotopic GL261 gliomas, M@PLGA‐ 10 BN delivers 53.15 µg/g 10 B to tumors – 3.09‐fold higher than uncoated nanoparticles – with tumor‐to‐normal/brain (T/N) and tumor‐to‐blood (T/B) ratios of 3.95 and 3.85, respectively. Neutron irradiation extends survival by 50 days and triggers immunogenic cell death, increasing tumor‐infiltrating CD8 + T cells 4.2‐fold while reducing regulatory T cells (Tregs) by 68%. Crucially, BNCT‐induced PD‐L1 upregulation provides a mechanistic basis for combining with anti‐PD‐1 immunotherapy, achieving complete tumor regression in 50% of mice. By concurrently overcoming the blood‐brain barrier and immunosuppression, this biomimetic strategy unlocks new clinical horizons for BNCT, establishing a new paradigm for treating CNS malignancies.

Subjects

MeSH terms (MEDLINE)

GlioblastomaBoron Neutron Capture TherapyNanoparticlesImmunotherapyBrain NeoplasmsMacrophagesCell MembraneAnimalsMiceBlood-Brain BarrierCell Line, TumorHumansBiomimetics

Author keywords

biomimetic nanoparticlesblood‐brain barrierboron neutron capture therapyglioblastomaimmunotherapy

Authors and institutions

  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Neurosurgical Institute, Fudan University, Shanghai, China.
  • Shanghai Clinical Medical Center of Neurosurgery, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China.
  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Brain Function and Disorders and MOE Frontiers Center For Brain Scien…
  • School of Nuclear Science and Technology, Lanzhou University, Lanzhou, China.
  • Shanghai ImmunoBiotech Co., Ltd., Shanghai, China.

ORCID profiles: Shan Jiang, Houshi Xu, Tao Sun

Funding

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Excellent project of Shanghai Municipal Health Commission
  • Medical innovation research project of Shanghai Science and Technology Commission
  • Dawn Program of Shanghai Education Commission
  • Fudan University Medical Engineering Integration Project
  • Research Institute Fund of Chinese Academy of Medical Sciences

Cite

APA

Chen, J., You, H., Huang, H., Chai, H., Zhu, R., Guan, Y., Tang, Q., Li, T., Jiang, S., Xu, H., Wang, P., Wang, Y., Sun, M., Liu, B., Li, Z., Zeng, Y., Ping, W., Teng, Y., Yan, S., …, & Shi, Z. (2026). Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.76216

Vancouver

Chen J, You H, Huang H, Chai H, Zhu R, Guan Y, et al. Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.76216

BibTeX
@article{Chen2026,
  author = {Chen, Jiawen and You, Haoyu and Huang, Hefa and Chai, Huihui and Zhu, Ruize and Guan, Yun and Tang, Qisheng and Li, Tianwen and Jiang, Shan and Xu, Houshi and Wang, Peng and Wang, Yue and Sun, Maoyuan and Liu, Beining and Li, Zhen and Zeng, Yulai and Ping, Weiqiu and Teng, Yanlin and Yan, Songlin and Li, Qinghui and Gu, Long and Sun, Tao and Shi, Zhifeng},
  title = {Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76216}
}
Start for free →